Lonza hopes that the new business it has set up in China will help cement its position as a leading provider of services to the country’s pharmaceutical manufacturing sector.
Lonza's $200m (€147m) investment in China is continuing to shape up
as the firm announced its new small-scale exclusive synthesis
manufacturing plant will be up and running next month.
Chemicals firm Lonza has vowed to spend $200m (€160m) over the next
few years to expand in southern China, further limiting its
dependence on external suppliers of intermediates and active
pharmaceutical ingredients (APIs).
Switzerland's Lonza has boosted its ability to make active
pharmaceutical ingredients (API) at its Visp site in response to
what it said was 'ever increasing hygienic and regulatory
requirements'.
Foreign drugmakers are failing to win ground against their local
counterparts in China, despite investing considerable sums in the
country over the last few years.